La cuestión de cuánto tiempo nos queda de vida es una incógnita que ha intrigado a la humanidad durante siglos. Si bien no podemos predecir con precisión la fecha de nuestro último aliento, la ciencia ha avanzado considerablemente en el campo de la longevidad y las …
El concepto del multiverso, la idea de que existen múltiples universos en el vasto tejido del espacio-tiempo, implica preguntas fascinantes. Por ejemplo, ¿qué condiciones deben existir en un universo para que sea viable para la vida? 1. La Constante Cosmológica: …
¿Cómo deberían ser los universos en un multiverso para albergar vida? Read More »
BioRay Pharmaceutical Co., Ltd. announced that the first patient has been dosed in the Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate targeting LIV-1 for the treatment of advanced malignant tumors.
Clover Biopharmaceuticals, Ltd. announced the company completes the Biologic License Application submission for its seasonal influenza vaccine to Brazilian Health Regulatory Agency.
Clover Completes BLA Submission for Seasonal Influenza Vaccine in Brazil Read More »
Innate Pharma SA announced that the Company will hold a conference call on Tuesday, November 14, 2023, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2023.
Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update Read More »
IRLAB Therapeutics AB announced that the nomination committee ahead of the annual general meeting 2024 have been appointed.
Nomination Committee Appointed for IRLAB’s Annual General Meeting 2024 Read More »
Antech, the full-service veterinary diagnostics business that is part of the Science & Diagnostics division of Mars Petcare, announced the opening of a new UK veterinary diagnostics laboratory in Warwick on 15 November.
Abbisko Therapeutics Co., Ltd. announced that two major clinical updates of its CSF-1R inhibitor pimicotinib (ABSK021) were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held in Ireland from November 1 to 4, 2023.
In August we were excited to see the full data set from our Phase 3 clinical trial, NefIgArd, published in The Lancet and we are looking forward to a potential full approval of TARPEYO for treatment of IgA Nephropathy, for which the PDUFA date is December 20, 2023.
Calliditas Interim Report January – September 2023 Read More »
BioArctic AB’s partner Eisai issued their quarterly report containing LEQEMBI sales for the third quarter 2023.
LEQEMBI® Q3 2023 sales published – 0.4 billion yen recorded in the period Read More »
